Cardiotoxic effects, or lack thereof, of anti‐ErbB2 immunoagents-Reference-Cited by-同舟云学术

Cardiotoxic effects, or lack thereof, of anti‐ErbB2 immunoagents

Published:2009-05-05 Issue:9 Volume:23 Page:3171-3178
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Riccio Gennaro¹,Esposito Giovanni²,Leoncini Emanuela³,Contu Riccardo⁴,Condorelli Gianluigi⁴,Chiariello Massimo²,Laccetti Paolo¹,Hrelia Silvana³,D'Alessio Giuseppe¹,De Lorenzo Claudia¹

Affiliation:

1. Dipartimento di Biologia Strutturale e Funzionale Università di Napoli Federico II Naples Italy

2. Dipartimento di Medicina Clinica Scienze Cardiovascolari ed Immunologiche Università di Napoli Federico II Naples Italy

3. Dipartimento di Biochimica “G.Moruzzi,” Università di Bologna Bologna Italy

4. Istituto Ricovero e Cura a Carattere Scientifico Multimedica Milan Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero dell’Istruzione, dell’Università e della Ricerca

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.09-131383

Reference28 articles.

1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

2. Herceptin (trastuzamab) in advanced breast cancer

3. Current and planned clinical trials with trastuzumab (Herceptin);Baselga J.;Semin. Oncol.,2000

4. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

5. Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review;Human Immunology;2024-09

2. Label-free electrochemical cancer cell detection leveraging hemoglobin-encapsulated silver nanoclusters and Cu-MOF nanohybrids on a graphene-assisted dual-modal probe;Scientific Reports;2023-12-11

3. HER2-Targeted Therapy—From Pathophysiology to Clinical Manifestation: A Narrative Review;Journal of Cardiovascular Development and Disease;2023-12-06

4. Trastuzumab-induced human cardiomyocyte damage through the Notch2/JAK2/STAT3 pathway;Clinics;2023-01

5. Cardiac fibrosis in oncologic therapies;Current Opinion in Physiology;2022-10